COMPASS Experiment at CERN Chooses the MAPD-3N

Zecotek’s New-Generation Micro-pixel Avalanche Photo Diodes Chosen by the COMPASS Experiment at CERN

Singapore, December 13, 2012 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the COMPASS experiment at CERN has selected the Company’s solid-state MAPD-3N photo detectors, for the multi-purpose experiment in high-energy physics taking place at CERN’s Super Proton Synchrotron accelerator located in Switzerland. The MAPD-3N will be used in the electromagnetic calorimeter. COMPASS and other experiments at CERN are demanding higher energies than ever before and require five key parameters for photo detectors: low cost, high photo-detection efficiency, very high linearity, significant radiation hardness, and a low recovery time. Zecotek’s solid-state MAPD-3N photo detectors meet all of the parameters including an optimum low recovery time, which has been fine tuned to a level commanded by all CERN experiments.

“The MAPD-3N was successfully used by the Joint Institute for Nuclear Research and will now be used for the main COMPASS calorimeter due toits unique dynamic range and reliable operation,” said Prof. Alexander Olshevskiy, Senior Scientist and Director of Research. “The full size COMPASS calorimeter is being constructed for the next data taking period and will consist of about 2000 towers. With the success achieved by the Large Hadron Collider and other experiments, finding a photo detector that meets all our requirements for future experiments is a very important step.”

“CERN is in its 58th year and the technical challenges put forward over the past few years by CERN engineers and scientists have been progressively growing,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “The results of the past few months have forced the main solid-state photo detector developers to go back to the drawing board and design a photo-detector that meets all of CERN’s upgraded requirements. The determination and unique expertise of the Zecotek scientific team plus our intellectual property have permitted Zecotek to meet all the challenges put forth and take the lead in developing a lower cost, solid-state photo detector with high photo-detection efficiency, very high linearity, significant radiation hardness, and an optimum low recovery time.”

CERN experiments have observed a particle consistent with the long sought after Higgs boson, but more work and analysis is necessary to prove the existence of the Standard Model Higgs. The possible sighting of the Higgs boson has created much excitement and intrigue. The popular opinion amongst scientists is that supersymmetry particles and other exotic objects, like the Higgs boson, can only be seen at much higher energies than those currently used by the Large Hadron Collider (LHC). Zecotek has been working closely with CERN scientists and engineers to meet the new requirements in all major experiments. With CERN closing down the LHC at year’s end for general maintenance, Zecotek is scheduled to deliver the first MAPD-3Ns in the first quarter of 2013.

Zecotek’s proprietary solid-state MAPD-3N photo detector is a design upgrade of the previously announced MAPD. It offers significant performance-cost advantages over competing photomultiplier tubes (PMT) and other solid-state, silicon based photo-detectors. With improved recovery time, unique radiation hardness, photo-detection efficiency and its display of the highest possible linearity, it is a prime component for the improved detector designs required in the next crucial phase of high energy experiments at CERN. Its lower manufacturing cost, excellent timing resolution and Photon Detection Efficiency are also key characteristics for the new configurations of high resolution PET (Positron Emission Tomography) scanners.

The MAPD-3N is supplied to customers through Zecotek Imaging Systems Pte. Ltd., Singapore, a wholly owned subsidiary of Zecotek Photonics Inc., and manufactured under contract by the NNFC; National NanoFab Center, Daejeon City, South Korea.

-30-

About COMPASS
COMPASS is a high-energy physics experiment at the Super Proton Synchrotron (SPS) at CERN in Geneva, Switzerland. The purpose of this experiment is the study of hadron structure and hadron spectroscopy with high intensity muon and hadron beams. Nearly 240 physicists from 11 countries and 28 institutions work in COMPASS.

About CERN
CERN, the European Organization for Nuclear Research, is one of the world’s largest and most respected centres for scientific research. Its business is fundamental physics, finding out what the Universe is made of and how it works. At CERN, the world’s largest and most complex scientific instruments are used to study the basic constituents of matter — the fundamental particles. By studying what happens when these particles collide, physicists learn about the laws of Nature. CERN is the home of the Large Hadron Collider (LHC). LHC experiments will address questions such as what gives matter its mass, what the invisible 96% of the Universe is made of, why nature prefers matter to antimatter and how matter evolved from the first instants of the Universe’s existence. Founded in 1954, the CERN Laboratory sits astride the Franco–Swiss border near Geneva. It was one of Europe’s first joint ventures and now has 20 Member States. For more information please visit http://press.web.cern.ch/press-releases.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanner technologies, 3D auto-stereoscopic displays, fiber lasers and waveguide micro lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisional companies: Zecotek Imaging (medical, industrial and research), Zecotek Lasers (industrial and research) and Zecotek 3D (monitors for multimedia, entertainment, industrial and medical). The Company has labs located in Canada, Singapore and Russia, with affiliated R&D and production facilities in USA, China, and South Korea. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances with multinational OEMs, distributors and other industry leaders. For more information, visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.